… attack, heart failure, cardiac failure, randomized controlled trial and RCT. Detailed search
strategy was as follows: (sacubitril-valsartan OR valsartan-… used to assess the ventricular …

… , open label sacubitril/valsartan use was anticipated to confound the recurrent event … use of
open label sacubitril/valsartan (<10%) in patients developing symptomatic heart failure during …

… treatment of cardiovascular disease, heart failure with reduced ejection fraction (HFrEF)
following acute myocardial infarction … used a single dose of 20 mg/kg SAC/VAL for oral treatment …

… with risk of cardiovascular death or incident heart failure. … , and β-blockers, also attenuate
post–myocardial infarction (MI) LV … Use of other cardiovascular medications was also similar …

… Danshen has been used for the treatment of various diseases… For this reason we chose
valsartan as positive control in this … alleviate LAD-induced post-myocardial infarction remodeling. …

… combination with sodium-glucose co-transporter 2 inhibitors or in post-myocardial infarction
HF. … , a wider and earlier use of S/V in the management of HF patients should be considered. …

… risk of cardiovascular death or heart failure admission in patients with myocardial infarction
(MI) and left ventricular systolic dysfunction (LVSD) combined with either heart failure (HF) or …

… Post-myocardial infarction heart failure (post-MI HF) is a common, life-threatening complication
in patients … All data in this study were used to determine the means and SDs. Student's t …

… left ventricular remodeling post-myocardial infarction is correlated to the risk of heart failure
(HF), which … Third, this study emphasizes that timely use of relevant drugs in patients with AMI …

… HF and post-MI trials of sacubitril-valsartan. Similarly, multiple trials of early and aggressive
use of therapies effective in chronic heart failure immediately post-MI failed to demonstrate …